F. El Hajbi - Centre Oscar Lambret | 人才画像

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 41 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Nivolumab (NIVO) Plus Chemotherapy (chemo) or Ipilimumab (IPI) Vs Chemo As First-Line (1L) Treatment for Advanced Esophageal Squamous Cell Carcinoma (ESCC): 45-Month (mo) Follow-Up from CheckMate 648

Ian Chau,Jaffer A. Ajani,Yuko Kitagawa,Jianming Xu,Lucjan S. Wyrwicz,Satoru Motoyama,Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu,Antoine Adenis,Farid El Hajbi,Maria Di Bartolomeo,Maria Ignez Braghiroli,Eva Holtved,Mariela A. Blum Murphy, Raheel Nathani,Nan Hu,Yasuhiro Matsumura,Ken Kato,Yuichiro Doki

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0Bibtex

FOLFIRI Plus Durvalumab with or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: the PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial

David Tougeron,Laetitia Dahan,Ludovic Evesque,Karine Le Malicot,Farid El Hajbi,Thomas Aparicio,Olivier Bouche, Nathalie Bonichon Lamichhane,Benoist Chibaudel,Antoine Angelergues,Anais Bodere,Jean-Marc Phelip,May Mabro,Laure Kaluzinski,Caroline Petorin,Gilles Breysacher,Yves Rinaldi,Aziz Zaanan,Denis Smith,Marie-Claude Gouttebel, Clement Perret, Nicolas Etchepare,Jean-Francois Emile, Ivan Sanfourche,Frederic Di Fiore,Come Lepage,Pascal Artru,Christophe Louvet

JAMA ONCOLOGY (2024)

Cited0Views0WOSBibtex

Nivolumab (NIVO) Plus Chemotherapy (chemo) or Ipilimumab (IPI) Vs Chemo As First-Line (1L) Treatment for Advanced Esophageal Squamous Cell Carcinoma (ESCC): 29-Month (mo) Follow-Up from CheckMate 648

Ken Kato,Jaffer A. Ajani,Yuichiro Doki, Jianming Xu,Lucjan Wyrwicz,Satoru Motoyama,Takashi Ogata, Hisato Kawakami,Chih-Hung Hsu,Antoine Adenis,Farid El Hajbi,Maria Di Bartolomeo,Maria Ignez Freitas Melro Braghiroli,Eva Holtved,Mariela A. Blum Murphy,Apurva Patel, Nan Hu,Yasuhiro Matsumura,Ian Chau, Yuko Kitagawa

Journal of clinical oncologyno. 4_suppl (2023): 290-290

Cited2Views0Bibtex

Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon

Benoit Rousseau,Ivan Bieche, Eric Pasmant,Nadim Hamzaoui,Nicolas Leulliot,Lucas Michon,Aurelien de Reynies, Valerie Attignon,Michael B. Foote,Julien Masliah-Planchon,Magali Svrcek,Romain Cohen,Victor Simmet,Paule Augereau,David Malka,Antoine Hollebecque,Damien Pouessel,Carlos Gomez-Roca, Rosine Guimbaud,Amandine Bruyas,Marielle Guillet,Jean-Jacques Grob,Muriel Duluc,Sophie Cousin,Christelle de la Fouchardiere,Aude Flechon,Frederic Rolland,Sandrine Hiret,Esma Saada-Bouzid,Olivier Bouche,Thierry Andre,Diane Pannier,Farid El Hajbi,Stephane Oudard,Christophe Tournigand, Jean-Charles Soria,Stephane Champiat,Drew G. Gerber,Dennis Stephens,Michelle F. Lamendola-Essel,Steven B. Maron,Bill H. Diplas, Guillem Argiles,Asha R. Krishnan,Severine Tabone-Eglinger,Anthony Ferrari,Neil H. Segal,Andrea Cercek,Natalie Hoog-Labouret,Frederic Legrand,Clotilde Simon,Assia Lamrani-Ghaouti,Luis A. Diaz,Pierre Saintigny,Sylvie Chevret,Aurelien Marabelle

openalex（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn